Short Interest in CSL Limited (OTCMKTS:CSLLY) Expands By 189.9%

CSL Limited (OTCMKTS:CSLLY) saw a significant increase in short interest in February. As of February 28th, there was short interest totalling 20,000 shares, an increase of 189.9% from the February 13th total of 6,900 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 216,000 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group raised CSL to a “strong-buy” rating in a report on Thursday, January 16th.

CSL Trading Up 0.7 %

CSL stock opened at $78.89 on Thursday. The business’s 50 day simple moving average is $84.23 and its 200 day simple moving average is $91.52. CSL has a 12 month low of $77.37 and a 12 month high of $109.00. The company has a current ratio of 2.18, a quick ratio of 0.97 and a debt-to-equity ratio of 0.58.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.